APA (7th ed.) Citation

M, K., N, P., R, F., A, N., SJ, H., M, H., . . . JF, S. (2017). Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia & lymphoma, 58(2), 298. https://doi.org/10.1080/10428194.2016.1190971

Chicago Style (17th ed.) Citation

M, Kenealy, et al. "Results of a Phase II Study of Thalidomide and Azacitidine in Patients with Clinically Advanced Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Low Blast Count Acute Myeloid Leukemia (AML)." Leukemia & Lymphoma 58, no. 2 (2017): 298. https://doi.org/10.1080/10428194.2016.1190971.

MLA (9th ed.) Citation

M, Kenealy, et al. "Results of a Phase II Study of Thalidomide and Azacitidine in Patients with Clinically Advanced Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Low Blast Count Acute Myeloid Leukemia (AML)." Leukemia & Lymphoma, vol. 58, no. 2, 2017, p. 298, https://doi.org/10.1080/10428194.2016.1190971.